TITLE

Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy

AUTHOR(S)
Simonds, A. K.; Muntoni, F.; Heather, S.; Fielding, S.
PUB. DATE
November 1998
SOURCE
Thorax;Nov1998, Vol. 53 Issue 11, p949
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66299223

 

Related Articles

  • Change in Natural History of Duchenne Muscular Dystrophy With Long-term Corticosteroid Treatment: Implications for Management. Moxley, Richard T.; Pandya, Shree; Ciafaloni, Emma; Fox, Deborah J.; Campbell, Kim // Journal of Child Neurology;Sep2010, Vol. 25 Issue 9, p1116 

    In 2005, the American Academy of Neurology and the Child Neurology Society published a practice parameter, based primarily on studies that involved 6 to 18 months of treatment, indicating that prednisone has a beneficial effect on muscle strength and function in patients with Duchenne muscular...

  • The Becker type X-linked muscular dystrophy.  // British Medical Journal;12/18/1976, Vol. 2 Issue 6050, p1465 

    Examines the different forms of muscular dystrophy in Great Britain. Difficulties brought by Duchenne muscular dystrophy; Comparison between Duchenne and Becker muscular dystrophy; Presence of cardiomyopathy in Duchenne muscular dystrophy.

  • Respiratory care in muscular dystrophy. Heckmatt, J.Z. // British Medical Journal (Clinical Research Edition);10/24/1987, Vol. 295 Issue 6605, p1014 

    Examines the respiratory care in Duchenn muscular dystrophy in Great Britain. Description of Duchenn muscular dystrophy; Symptoms of the disease; Causes of the disease.

  • Special Issue—Towards Understanding the Mechanisms and Curing of Muscular Dystrophy Diseases. Phyla, Leonidas A. // Molecules;Jul2015, Vol. 20 Issue 7, p12944 

    An introduction is presented in which the editor discusses various reports within the issue on topics including methods for the identification of biomarkers in Duchenne Muscular Dystrophy, the impact of cell culture to gene expression, and management of muscular dystrophy through model organisms.

  • Recognising and preventing Duchenne muscular dystrophy. Gardner-Medwin, David // British Medical Journal (Clinical Research Edition);10/15/1983, Vol. 287 Issue 6399, p1083 

    Examines the incidence and prevention of Duchenne muscular dystrophy. Manifestations of the disease; Impact of counselling on the patient and family members; Observation of motor development to detect the occurrence of the disease.

  • CME Questions.  // Neurology Alert;Jan2011, Vol. 29 Issue 5, p39 

    A quiz about neurological issues is presented including dementia and Duchenne muscular dystrophy.

  • Corticosteroids for Children with Duchenne’s Muscular Dystrophy. T., H. // School Health Alert;Jan2014, Vol. 29 Issue 5, p7 

    The article offers information on a study on the effectiveness of corticosteroids on children with Duchenne's muscular dystrophy.

  • dystrophinopathy.  // Taber's Cyclopedic Medical Dictionary;2005, p655 

    A definition of the medical term "dystrophinopathy" is presented, which means Duchenne's muscular dystrophy.

  • The Muscular Dystrophy Family Foundation, Inc. Duncan, Judith R. // Exceptional Parent;Jun2002, Vol. 32 Issue 6, p90 

    Features the Muscular Dystrophy Family Foundation Inc. Description of Duchenne muscular dystrophy; Mission of the company; Services provided by the foundation.

  • Consensus on Duchenne care.  // Speech & Language Therapy in Practice;Spring2010, p3 

    The article reports that Action Duchenne obtained an international consensus document "Diagnosis and Management of Duchenne Muscular Dystrophy" for best practice in care.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics